

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: NE-0004

Inventors: Hollingsworth et al.

Serial No.: 10/618,481

Filing Date: July 11, 2003

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Title: Compositions and Methods for Preventing  
or Treating Cancer

I, Jane Massey Licata, Registration No. 32,257,  
certify that this correspondence is being deposited  
with the U.S. Postal Service as First Class mail in  
an envelope addressed to the Commissioner for Patents  
P.O. Box 1450, Alexandria, VA 22313-1450

On this date: October 23, 2003

Jane Massey Licata  
Jane Massey Licata, Registration No. 32,257

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified

application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

( ) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

( ) Certification in Accordance with §1.97(e) is attached hereto; or

( ) The fee of \$180.00 as set forth in §1.17(p) is attached.

( ) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I) (1).

(XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

( ) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. \_\_\_\_\_, filed \_\_\_\_\_, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

( ) The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,

*Jane Massey Licata*

Jane Massey Licata  
Registration No. 32,257

Date: October 23, 2003

Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, New Jersey 08053

(856) 810-1515



Sheet 01 of 03

<b>Form PTO-1449 Modified</b>  List of Patents and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce	Docket No. <b>NE-0004</b>	Serial No. <b>10/618,481</b>
	Applicant <b>Hollingsworth et al.</b>	
	Filing Date <b>July 11, 2003</b>	Group <b>Not Yet Assigned</b>


**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
	AA	5,744,144	4-28-98	Finn et al.	424	277.1
	AB	5,827,666	10-27-98	Finn et al.	435	7.1
	AC	4,963,484	10-16-90	Kufe	435	69.3
	AD	6,344,203	2-5-02	Sandrin et al.	424	277.1

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Translation YES NO	
	AE	WO 88/05054	14-7-88	PCT	x	

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------



Form PTO 1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce		Docket No. <b>NE-0004</b>	Serial No. <b>10/618,481</b>
		Applicant <b>Hollingsworth et al.</b>	
		Filing Date <b>July 11, 2003</b>	Group <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	BA	Brossart et al., "Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells", Blood 2000 96(9):3102-3108	
	BB	Brossart et al., "Identification of HLA-A1-Restricted T-Cell Epitopes Derived From the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies", Blood 1999 93(12):4309-4317	
	BC	Chen et al., "Experimental Vaccine Strategies for Cancer Immunotherapy", J. Biomed Sci. 1998 5:231-252	
	BD	Croce et al., "Expression of Tumour Associated Antigens in Normal, Benign and Malignant Human Mammary Epithelial Tissue:A Comparative Immunohistochemical Study", Anticancer Research 1997 17:4287-4292	
	BE	Finn et al., "MUC-1 Epithelial Tumor Mucin-Based Immunity and Cancer Vaccines", Immunological Reviews 1995 145:61-89	
	BF	Graham et al., "The polymorphic epithelial mucin:potential as an immunogen for a cancer vaccine", Cancer Immunol. Immunother 1996 42:71-80	
	BG	Graham et al., "Intramuscular Immunisation with MUC1 cDNA can Protect C57 Mice Challenged with MUC1-Expressing Syngeneic Mouse Tumour Cells", Int. J. Cancer 1996 54:664-670	
	BH	Heukamp et al., "Identification of Three Non-VNTR MUC1-Derived HLA-A*0201-Restricted T-Cell Epitopes that Induce Protective Anti-Tumor Immunity in HLA-A2/K <sup>b</sup> -Transgenic Mice", Int. J. Cancer 2001 91:385-392	
	BI	Heukamp et al., "Effective Immunotherapy of Cancer in MUC1-Transgenic Mice Using Clonal Cytotoxic T Lymphocytes Directed Against an Immunodominant MUC1 Epitope", Journal of Immunotherapy 2002 25(1):46-56	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	



Form <del>PTO 1449</del> Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce		Docket No. <b>NE-0004</b>	Serial No. <b>10/618,481</b>
		Applicant <b>Hollingsworth et al.</b>	
		Filing Date <b>July 11, 2003</b>	Group <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	BJ	Morikane et al., "Organ-specific pancreatic tumor growth properties and tumor immunity", Cancer Immunol. Immunother 1999 47:287-296	
	BK	Morikane et al., "Influence of organ site and tumor cell type on MUC1-specific tumor immunity", International Immunology 2001 13(2):233-240	
	BL	Reddish t al., "Anti-MUC1 Class I Restricted CTLs in Metastatic Breast Cancer Patients Immunized with a Synthetic MUC1 Peptide", Int.J. Cancer 1998 76:817-823	
	BM	Rowse et al., "Tolerance and Immunity to MUC1 in a Human MUC1 Transgenic Murine Model <sup>1</sup> ", Cancer Research 1998 58:315-321	
	BN	Sivinski et al., "Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines", Cancer Immunol. Immunother 2002 51:327-340	
	BO	Tempero et al., "CD4 <sup>+</sup> Lymphocytes Provide MUC1-Specific Tumor Immunity In Vivo That Is Undetectable In Vitro and Is Absent in MUC1 Transgenic Mice <sup>1</sup> ", J. Immunology 1998 161:5500-5506	
	BP	Tempero et al., "Passively transferred anti-MUC1 antibodies cause neither autoimmune disorders nor immunity against transplanted tumors in MUC1 transgenic mice", International Journal of Cancer 1999 80(4):595-599	
	BQ	VanLith et al., "MUC1-specific anti-tumor responses:molecular requirements for CD4-mediated responses", International Immunology 2002 14(8):873-882	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	